Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
輝瑞公司（NYSE:PFE）週二報告，第二季度調整後每股收益爲0.60美元，同比下降11％，超過了0.46美元的共識預測。
The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
這家美國製藥公司報告說，銷售額爲132.8億美元，同比增長2％（運營上增長3％），超過了130.2億美元的共識預測。
The increase was primarily due to growth contributions from several of our acquired products, key in-line products, and recent commercial launches, which more than offset both an expected decline in Comirnaty.
增長主要歸功於我們收購的幾種產品、主要的在售產品和最近推出的商業產品的增長貢獻，這些增長貢獻超過了Comirnaty預期的下降。
Also Read: Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study.
此外，桑甘莫股票因Pfizer合作伙伴在後期研究中達成目標而暴漲。
Excluding contributions from Comirnaty and Paxlovid, revenues reached $12.8 billion, increased 14% operationally.
除Comirnaty和Paxlovid二者的貢獻外，收入增加至128億美元，運營上增長14％。
In the second quarter of 2024, Comirnaty's revenues of $195 million declined by 87%. Paxlovid revenues increased 79% to $251 million.
2024年第二季度，Comirnaty的收入爲19500萬美元，下降了87％。 Paxlovid的收入增長了79％，達到了25100萬美元。
Vyndaqel family drugs generated sales of $2.46 billion, up 68%. Eliquis, a blood thinner drug, generated sales of $3.92 billion, up 9%.
Vyndaqel系列藥品的銷售額爲24.6億美元，增加了68％。一種血液減薄機藥物Eliquis的銷售額爲39.2億美元，增長了9％。
Albert Bourla, Chairman and Chief Executive Officer, stated, "Notably, we achieved exceptional growth in our Oncology portfolio, with strong revenue contribution from our legacy-Seagen products."
董事長兼首席執行官Albert Bourla表示：“值得注意的是，我們在腫瘤學領域實現了卓越的增長，我們的傳統Seagen產品爲收入做出了重要貢獻。”
"In the second quarter, for example, we achieved year-over-year revenue growth for the first time since the fourth quarter of 2022 when our COVID revenues peaked," Bourla added.
“例如，在第二季度，我們首次實現了自2022年第四季度COVID收入峯值以來的同比收入增長，” Bourla補充道。
In May, Pfizer launched a multi-year cost-cutting initiative to save approximately $1.5 billion by the end of 2027.
五月，輝瑞啓動了一項爲期多年的成本削減倡議，計劃到2027年節省約15億美元。
Guidance: Pfizer updates its 2024 revenue forecast to $59.5 billion—$62.5 billion, compared to prior guidance of $58.5 billion—$61.5 billion and consensus of $60.7 billion.
指引：輝瑞更新其2024年營收預測爲595億-625億美元，相比之前的指引585億-615億美元和共識預測607億美元。
The company's updated guidance includes approximately $8.5 billion (vs. $8 billion expected earlier) in anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $3.5 billion, respectively.
公司的更新指導包括約85億美元的預期Comirnaty和Paxlovid收入（比早期預期的80億美元多約5億美元），分別約爲50億美元和35億美元。
Pfizer expects 2024 operational revenue growth of 9%- 11% year over year, up from 8%- 10% provided on January 30, 2024.
輝瑞預計2024年運營收入同比增長9％-11％，高於2024年1月30日提供的8％-10％。
Pfizer expects 2024 adjusted EPS of $2.45-$2.65 compared to prior guidance of $2.15-$2.35 and consensus of $2.37.
輝瑞預計2024年調整後每股收益爲2.45-2.65美元，相比之前的指引2.15-2.35美元和共識預測2.37美元。
Price Action: PFE stock is up 1.60% at $31.21 during the premarket session at the last check on Tuesday.
股價走勢：週二盤前交易時，PFE股票上漲1.60％，最後一次交易價格爲31.21美元。
- With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence – Goldman Sachs.
- 隨着口服抗肥胖候選藥物開發，輝瑞尋求相關和有競爭力的存在 - 高盛。
Photo via Wikimedia Commons
照片通過Wikimedia Commons